There were more than 18 million cancer survivors in the United States at the beginning of this year, according to new data.
The prevalence of pregnancy with cancer increased 13.8% from 2016 to 2019.
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
Higher total fish intake, tuna intake, and nonfried fish intake were all positively linked to the risk of malignant melanoma and melanoma in situ.
The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.
The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.
The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
In all, 32 patients had a response, translating to an ORR of 66.7%.
The higher response rates with concurrent therapy did not translate to improvements in survival.
Pembrolizumab significantly improved distant metastasis-free survival and reduced recurrence in stage IIB and IIC melanoma.
Researchers sought to determine if the incidence of melanoma diagnoses and biopsies increased with a greater uptake of skin screenings.
Younger age, female sex, increased disease severity, and having a significant other to help with exams may improve compliance.
Although skin cancer is one of the most preventable cancers, there are knowledge gaps about sun protection that need to be addressed.
The skin microbiome may serve as biomarker for skin cancer progression.
In a phase 2 study, researchers are investigating the combination of cryoablation and dual checkpoint inhibition.
Researchers sought to investigate the connection between immune checkpoint inhibitors (ICIs) and immune- and autoimmune-related adverse events in older patients diagnosed with melanoma.
The updated guideline reviews advanced radiation therapy techniques and places emphasis on multidisciplinary care.
The intervention would yield a net monetary benefit of £10.6 million and a net health benefit of 530 QALYs, researchers found.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.